Analyst consensus rating
Atea Pharmaceuticals Analyst Rating: none
AVIR is rated none by 3 analysts with a $9.42 target. As of 2026-09-01.
Direct answer
Atea Pharmaceuticals's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.42.
Forecast evidence checked September 1, 2026.
Get free Atea Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.35
- Average price target
- $9.42
- High price target
- $11.25
- Low price target
- $7.00
- Low target gap
- +30.8%
- Target upside
- +76%
- High target gap
- +110.3%
- Target range width
- 79.4%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Atea Pharmaceuticals?
Atea Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $9.42.
How far are Atea Pharmaceuticals's low and high targets from the recorded price?
The low target implies +30.8%, while the high target implies +110.3%.
How many analysts are included in Atea Pharmaceuticals's consensus?
The verified consensus includes 3 analysts.
How is Atea Pharmaceuticals's target upside or downside calculated?
The average target of $9.42 is divided by the recorded price of $5.35, then one is subtracted to produce +76%. This does not guarantee a future return.
When was Atea Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.